EGFR and non-small cell lung carcinoma: In the past decade, immune checkpoint inhibitors (ICIs) have exhibited substantial clinical efficacy as standard treatment options among patients with driver gene-negative (EGFR-) advanced and locally advanced NSCLC [7–10].